Log In
Print
BCIQ
Print
Print this Print this
 

JNJ56914845 (formerly 2336805, GSK2336805)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionHCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection; Treat non-cirrhotic, treatment-naïve patients with chronic HCV genotype 1 infection
Regulatory Designation

Partner

Johnson & Johnson


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today